Shots:

• Bridge to receive $50.66M as up front and near-term payments- up to $1.23B based on development- regulatory- and commercial milestones and royalties on sales
• The focus of the collaboration is to develop Bridge’s BBT-877 candidate and expand BI’s pipeline of fibrosing interstitial lung diseases in developing therapies for patients with Idiopathic Pulmonary Fibrosis (IPF) 
• BBT-877 is an autotaxin inhibitor targeted for the treatment of IPF- currently being evaluated in P-I expected to enter P-II within the next 12 months. In 2017- Bridge in-licensed BBT-877 from LegoChem Biosciences

Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Australia247